These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26688841)

  • 1. Neuroimaging and genetic correlates of cognitive dysfunction in multiple sclerosis.
    Guenter W; Jabłońska J; Bieliński M; Borkowska A
    Psychiatr Pol; 2015; 49(5):897-910. PubMed ID: 26688841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive impairment in multiple sclerosis - a review of current knowledge and recent research.
    Grzegorski T; Losy J
    Rev Neurosci; 2017 Nov; 28(8):845-860. PubMed ID: 28787275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive impairment in multiple sclerosis.
    Jongen PJ; Ter Horst AT; Brands AM
    Minerva Med; 2012 Apr; 103(2):73-96. PubMed ID: 22513513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cognitive impairment in multiple sclerosis].
    Karlińska I; Selmaj K
    Neurol Neurochir Pol; 2005; 39(2):125-33. PubMed ID: 15871058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis.
    Hynčicová E; Vyhnálek M; Kalina A; Martinkovič L; Nikolai T; Lisý J; Hort J; Meluzínová E; Laczó J
    J Neurol; 2017 Mar; 264(3):482-493. PubMed ID: 28028623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive Impairment in Multiple Sclerosis: Clinical Manifestation, Neuroimaging Correlates, and Treatment.
    Pflugshaupt T; Geisseler O; Nyffeler T; Linnebank M
    Semin Neurol; 2016 Apr; 36(2):203-11. PubMed ID: 27116727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis.
    Miller E; Morel A; Redlicka J; Miller I; Saluk J
    Curr Neuropharmacol; 2018; 16(4):475-483. PubMed ID: 29119933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does slowed processing speed account for executive deficits in multiple sclerosis? Evidence from neuropsychological performance and structural neuroimaging.
    Leavitt VM; Wylie G; Krch D; Chiaravalloti N; DeLuca J; Sumowski JF
    Rehabil Psychol; 2014 Nov; 59(4):422-8. PubMed ID: 25133903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cognitive impairment].
    Reuter F; Audoin B; Rico A; Malikova I; Ranjeva JP; Pelletier J
    Rev Neurol (Paris); 2009 Mar; 165 Suppl 4():S113-22. PubMed ID: 19361675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive impairment in multiple sclerosis.
    Chiaravalloti ND; DeLuca J
    Lancet Neurol; 2008 Dec; 7(12):1139-51. PubMed ID: 19007738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cognitive impairment in multiple sclerosis].
    Ochi H
    Brain Nerve; 2014 Oct; 66(10):1201-9. PubMed ID: 25296874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive deficits in multiple sclerosis: correlations with T2 changes in normal appearing brain tissue.
    Lund H; Jønsson A; Andresen J; Rostrup E; Paulson OB; Sørensen PS
    Acta Neurol Scand; 2012 May; 125(5):338-44. PubMed ID: 21793807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations.
    Rogers JM; Panegyres PK
    J Clin Neurosci; 2007 Oct; 14(10):919-27. PubMed ID: 17659875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association between depression and cognitive decline in sclerosis multiplex patients].
    Hegedüs K; Kárpáti J; Szombathelyi É; Simó M
    Neuropsychopharmacol Hung; 2015 Mar; 17(1):31-6. PubMed ID: 25935381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and Functional MRI Techniques in Multiple Sclerosis Related Cognitive Dysfunction.
    Iancheva D; Trenova A; Mantarova S; Terziyski K
    Folia Med (Plovdiv); 2018 Dec; 60(4):505-511. PubMed ID: 31188776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis.
    Yaldizli Ö; Penner IK; Yonekawa T; Naegelin Y; Kuhle J; Pardini M; Chard DT; Stippich C; Kira JI; Bendfeldt K; Amann M; Radue EW; Kappos L; Sprenger T
    Eur J Neurol; 2016 Mar; 23(3):510-9. PubMed ID: 26699999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive impairment and structural brain damage in benign multiple sclerosis.
    Rovaris M; Riccitelli G; Judica E; Possa F; Caputo D; Ghezzi A; Bertolotto A; Capra R; Falautano M; Mattioli F; Martinelli V; Comi G; Filippi M
    Neurology; 2008 Nov; 71(19):1521-6. PubMed ID: 18815387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalamic atrophy and cognitive impairment in clinically isolated syndrome and multiple sclerosis.
    Štecková T; Hluštík P; Sládková V; Odstrčil F; Mareš J; Kaňovský P
    J Neurol Sci; 2014 Jul; 342(1-2):62-8. PubMed ID: 24819917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive impairment in MS: rehabilitation approaches.
    Hämäläinen P; Rosti-Otajärvi E
    Acta Neurol Scand; 2016 Sep; 134 Suppl 200():8-13. PubMed ID: 27580900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortical thinning associated with mild cognitive impairment in Parkinson's disease.
    Segura B; Baggio HC; Marti MJ; Valldeoriola F; Compta Y; Garcia-Diaz AI; Vendrell P; Bargallo N; Tolosa E; Junque C
    Mov Disord; 2014 Oct; 29(12):1495-503. PubMed ID: 25100674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.